论文部分内容阅读
目的探讨恩替卡韦治疗乙型肝炎肝硬化的临床疗效。方法选取2010—2012南城县株良镇中心卫生院收治的乙型肝炎肝硬化患者68例,随机分为对照组与观察组,各34例。观察组患者予以恩替卡韦治疗,对照组患者予以替比夫定治疗。观察两组患者用药24、48、96周血清乙型肝炎病毒控制情况及不良反应发生情况。结果用药24、48、96周观察组患者乙型肝炎病毒控制率高于对照组,差异有统计学意义(P<0.05);两组患者均未发生严重不良反应。结论恩替卡韦治疗乙型肝炎肝硬化的临床疗效显著,可有效抑制乙型肝炎病毒复制,且不良反应少。
Objective To investigate the clinical efficacy of entecavir in the treatment of hepatitis B cirrhosis. Methods Sixty-eight patients with hepatitis B cirrhosis who were admitted to ZhuLiang Town Central Hospital, Nanchong County, 2010-2012 were randomly divided into control group and observation group, with 34 cases in each group. Patients in the observation group were treated with entecavir, and patients in the control group were treated with telbivudine. Two groups of patients were treated 24,48,96 weeks of serum hepatitis B virus control and adverse reactions. Results The control rate of Hepatitis B virus in observation group was higher than that of control group in 24, 48, and 96 weeks observation group (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Entecavir treatment of hepatitis B cirrhosis clinical efficacy was significant, can effectively inhibit the replication of hepatitis B virus, and less adverse reactions.